This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NeoStem Welcomes Dr. Adel Nada As Vice President, Immunotherapy

Stocks in this article: NBS

NEW YORK, April 3, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today the appointment of Dr. Adel Nada as Vice President, Immunotherapy. In this position, Dr. Nada will be responsible for developing the Company's T Regulatory Cell Program, which is investigating the use of T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in the immune system. The Company plans to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in the third quarter of 2014, as well as a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.

"We are very pleased that Dr. Nada has joined us, adding his expertise in immunology and clinical development to the growing NeoStem team," said Dr. Douglas Losordo, Chief Medical Officer of NeoStem. "Dr. Nada's experience strengthens our clinical programs at an important time as we launch new initiatives in diabetes and asthma."

Dr. Nada comes to NeoStem from Baxter Healthcare, where from 2012 to 2014 he was Senior Medical Director, Cardiovascular Cellular Therapies. Prior to joining Baxter, Dr. Nada worked at Abbott Laboratories from 2007-2012 where he was most recently responsible for the Clinical Pharmacology Medical Department. In this capacity, he led the cross functional group that provided instrumental strategic support for early clinical development across the entire company's pipeline. Working across different therapeutic areas, most notably antivirals, oncology, and immunology, he also led the clinical team developing a novel compound for rheumatoid arthritis.

"I am excited to join NeoStem's clinical development team at this key time as the company is planning to initiate two clinical trials for its T Regulatory Cell Program," said Dr. Nada. "I am pleased to bring my broad clinical development expertise to the program to help develop and execute upon the Company's vision for Treg therapies."

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs